

Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
NEW	Columvi (glofitamab-gxbm)	Positive	On June 15, 2023 the FDA granted accelerated approval to glofitamab-gxbm for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.	New FDA Drug/Indication
UM ONC_1070	Valstar (valrubicin)	No clinical change	Annual update	N/A
UM ONC_1208	Zytiga or Yonsa (abiraterone)	Positive	Annual update	New FDA Drug/Indication
UM ONC_1220	Arzerra (ofatumumab)	Pending	Annual update	
UM ONC_1224	Kyprolis (carfilzomib)	Pending	Annual update	
UM ONC_1228	Xtandi (enzalutamide)	Positive	On June 20, 2023 the FDA approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	New FDA Drug/Indication
UM ONC_1237	Cometriq or Cabometyx (cabozantinib)	Positive	Review requested (internal)	Other
UM ONC_1273	Lynparza (olaparib)	Pending	On May 31, 2023, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.	New FDA Drug/Indication
UM ONC_1274	Opdivo (nivolumab)	Positive	Review requested (internal)	Other
UM ONC_1280	Darzalex and Darzalex Faspro (daraumumab IV/SC)	No clinical change	Annual update	N/A
UM ONC_1325	Mylotarg (gemtuzumab ozogamicin)	No clinical change	Annual update	N/A
UM ONC_1341	Vizimpro (dacomitinib)	No clinical change	Annual update	N/A
UM ONC_1349	Talzenna (talazoparib)	Pending	On June 20, 2023 the FDA approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	New FDA Drug/Indication
UM ONC_1401	Tukysa (tucatinib)	Pending		
UM ONC_1406	Tabrecta (capmatinib)	No clinical change	Annual update	N/A